on Eckert & Ziegler Strahlen- Und Medizintechnik AG (ETR:EUZ)
Eckert & Ziegler Partners with Molecular Partners for Radio-DARPin Development
Eckert & Ziegler SE has announced a partnership with Molecular Partners AG to enhance the development and future manufacturing of Radio-DARPin therapeutics. These therapeutics are based on Molecular Partners' proprietary DARPin technology platform. The collaboration aims to advance the use of Actinium-225 and Lutetium-177 payloads, showing potential in cancer treatment.
Eckert & Ziegler will provide expertise through its state-of-the-art laboratories, including a new facility in Berlin. This partnership underscores Eckert & Ziegler's role as a leading partner in developing innovative radiopharmaceutical platforms.
Dr. Harald Hasselmann, CEO of Eckert & Ziegler, emphasized the significance of supporting innovative companies like Molecular Partners. This collaboration aligns with the company's goal of providing new treatment options worldwide.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Eckert & Ziegler Strahlen- Und Medizintechnik AG news